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Breast cancer is the primary cause of death by cancer in women worldwide and patients mostly die because of metastases appearance and development \[[@CR1]\] which rely in part on the ability of cancer cells to degrade and migrate through extracellular matrices (ECM). Currently, there is no treatment for specifically inhibiting metastases development. Voltage-gated sodium channels (Na~V~) are essential for action potential firing and as such are characteristic of excitable cells \[[@CR2]\]. However, different Na~V~ isoforms have been found in non-excitable epithelial human cancer biopsies and cells, such as in breast \[[@CR3], [@CR4]\], lung \[[@CR5]--[@CR7]\], prostate \[[@CR8]\], cervix \[[@CR9]\], ovarian \[[@CR10], [@CR11]\] and colon cancer \[[@CR12]\], and their function, through persistent currents at the membrane potential, enhances degradation of ECM \[[@CR5], [@CR13]--[@CR15]\]. Notably, the Na~V~1.5 isoform is abnormally expressed in breast cancer biopsies, while it is not in non-cancerous mammary tissues \[[@CR14]\], and its level of expression is associated with lymph node invasion, the development of metastases and a reduced survival of patients \[[@CR3], [@CR16], [@CR17]\]. In cancer cells, it is expressed as a neonatal splice variant showing a 7-amino acid substitution in the segments S3 and S4 of the domain I (DI-S3-S4) of the protein compared to the adult variant that shows a particular pharmacology \[[@CR18]\] and was proposed to serve as a metastatic marker \[[@CR16]\]. Na~V~1.5 is functional at the plasma membrane of highly invasive breast cancer cells \[[@CR3], [@CR16], [@CR17]\], and its activity maintains a pro-invasive phenotype \[[@CR15]\], related to "mesenchymal migration" \[[@CR19]\]. Indeed, while the complete mechanism involved is not yet elucidated, Na~V~1.5 activity was shown *i)* to control Src kinase activity, cortactin phosphorylation (Y421) and the subsequent polymerisation of actin filaments, *ii)* to increase the activity of the Na^+^/H^+^ exchanger type 1 (NHE-1), thus enhancing the efflux of protons and the proteolytic activity of extracellularly-released acidic cysteine cathepsins B and S \[[@CR13], [@CR20]\]. Altogether, these results indicated that Na~V~1.5 promotes the invadopodial activity of breast cancer cells and the invasion of the surrounding ECM \[[@CR15]\]. Molecules reducing its activity, such as tetrodotoxin, reduce cancer cell invasiveness *in vitro*\[[@CR3], [@CR14], [@CR18]\]. Correlatively, molecules that increase its activity, such as veratridine, enhance ECM invasion \[[@CR13]\]. However, to the best of our knowledge, the importance of Na~V~1.5 expression, and the relevance for its pharmacological inhibition, on the metastatic organ colonisation by breast cancer cells have never been reported so far. Ranolazine is an antiarrhythmic drug indicated for the treatment of chronic angina that was approved by the Food and Drug Administration (FDA) in 2006. While it is proposed to have several pharmacological actions, its best characterized one is the selective inhibition of late sodium currents \[[@CR21]\]. This leads to a steeper Na^+^ gradient which, by increasing the activity of the Na^+^/Ca^2+^ exchanger (NCX), reduces calcium overload, and improves ventricular relaxation in pathological conditions associated with cardiac ischemia \[[@CR22]\].

In this study we investigated how Na~V~1.5 expression in human breast cancer cells affected metastatic colonisation of organs in immunodepressed mice, and whether its pharmacological inhibition by ranolazine reduced cancer cell invasiveness both *in vitro* and *in vivo*.

Highly invasive MDA-MB-231 human breast cancer cells express mRNA for Na~V~1.5, Na~V~1.6 and Na~V~1.7 channels \[[@CR16]\], but only Na~V~1.5 channels are functional at the plasma membrane and are giving rise to transient inward sodium currents (INa) under voltage-clamp procedures \[[@CR13]\] (see Additional file [1](#MOESM1){ref-type="media"}: Material and methods). INa-voltage (INa-V) protocols were performed using the whole-cell configuration of the patch clamp technique from MDA-MB-231-Luc cells modified to stably express a null-target small hairpin RNA (shCTL). The INa-V relationship, obtained from a holding potential of −100 mV, indicated a threshold of activation around −60 mV and maximal current of −12.1 ± 2.2 pA/pF at a voltage of −10 mV (Figure [1](#Fig1){ref-type="fig"}A). The acute application of ranolazine (50 μM) significantly reduced the maximal amplitude to −8.7 ± 1.7 pA/pF (p \< 0.001). This decrease in the maximal current amplitude was associated with a significant leftward shift of the availability-voltage relationship (Figure [1](#Fig1){ref-type="fig"}B). The half (1/2)-inactivation voltage was shifted from −84.1 ± 1.4 mV to −90.3 ± 1.7 mV (p \< 0.001) in absence and presence of ranolazine, respectively. The activation-voltage relationship was significantly modified (Figure [1](#Fig1){ref-type="fig"}C), and the 1/2-activation voltage was shifted from −37.1 ± 1.0 mV to −39.2 ± 0.6 mV (p \< 0.01). Therefore, ranolazine reduced efficiently the activity of the neonatal Na~V~1.5 isoform expressed in human breast cancer cells. This isoform is the only one to be functional in breast cancer cells \[[@CR13], [@CR16]\] and we selected a population of cells stably expressing a small hairpin RNA targeting its expression (shNa~V~1.5) after lentiviral transduction. This led to a significant 89 ± 1% decrease of Na~V~1.5 mRNA expression (Figure [2](#Fig2){ref-type="fig"}A), resulting in the complete disappearance of sodium currents in almost all cancer cells (Figure [2](#Fig2){ref-type="fig"}B), with no effect on cell viability (Figure [2](#Fig2){ref-type="fig"}C). Before assessing the effect of ranolazine in reducing cancer cell invasiveness, we addressed a possible cytotoxic effect of its application. Figure [2](#Fig2){ref-type="fig"}D indicates that ranolazine, incubated for 5 days in a range of concentration from 0.1 to 100 μM had no effect on cell viability. It was then used at 50 μM in the 24 h invasion experiment with Matrigel™-coated filters (Figure [2](#Fig2){ref-type="fig"}E). In shCTL cells, cell invasiveness was reduced by 35 ± 4% with the total inhibition of Na~V~1.5 currents with 30 μM tetrodotoxin (TTX), and by 18 ± 3% with ranolazine. In comparison to shCTL cells, shNa~V~1.5 cancer cells, which do not express Na~V~1.5, had a reduced invasiveness of 33 ± 10%. In shNa~V~1.5 cells, both TTX and ranolazine were ineffective to further reduce cell invasiveness, suggesting that ranolazine was specific in inhibiting Na~V~1.5-related invasion. Na~V~1.5 expression and activity was recently shown to control the acquisition of a pro-invasive phenotype, by maintaining a spindle-shape morphology and by controlling the ECM proteolysis by MDA-MB-231 cancer cells \[[@CR15]\]. We found that ranolazine increased the circularity of shCTL cells, thus decreasing the pro-invasive morphology, to the same extent as the complete extinction of Na~V~1.5 expression (Figure [2](#Fig2){ref-type="fig"}F). Furthermore, ranolazine reduced the focal ECM degradative activity of shCTL cells by 58.6 ± 10.0% (Figure [2](#Fig2){ref-type="fig"}G). This activity, which is related to the invadopodial activity, was monitored as being the release of fluorescence from DQ-gelatin at focal sites of F-actin polymerisation as previously described \[[@CR15]\].Figure 1**Ranolazine inhibits sodium current in human breast cancer cells.** Sodium currents (INa) from MDA-MB-231 breast cancer cells stably expressing null target shRNA (shCTL) were studied in voltage-clamp mode with the whole-cell configuration of the patch clamp technique. **A**, Left, representative INa-voltage traces obtained from one cell before (vehicle) and after 50 μM ranolazine treatment (Rano). Right, mean ± s.e.m. steady-state INa-voltage relationships obtained from cancer cells before and after incubation with 50 μM ranolazine (n = 12 cells) from a holding potential of −100 mV. There is as statistical difference between the two conditions for voltages ranging from −35 to +40 mV (p \< 0.001, Wilcoxon test). **B**, Availability-voltage relationships obtained in presence (red trace) or not (vehicle, black trace) of 50 μM ranolazine. There is a significant leftward shift of the availability-voltage relationship in presence of ranolazine (p \< 0.001). The half (1/2)-inactivation voltage was shifted from −84.1 ± 1.4 mV to −90.3 ± 1.7 mV in absence and presence of ranolazine, respectively. **C**, Activation-voltage relationships obtained in presence (red trace) or not (vehicle, black trace) of 50 μM ranolazine. There is a significant leftward shift of the activation-voltage relationship in presence of ranolazine, and the 1/2-activation voltage was shifted from −37.1 ± 1.0 mV to −39.2 ± 0.6 mV in absence and presence of ranolazine, respectively. (p \< 0.01, Wilcoxon test).Figure 2**Ranolazine inhibits the Na** ~**V**~ **1.5-mediated breast cancer cell invasiveness** ***in vitro.*** **A**, *SCN5A* mRNA expression assessed by real-time qPCR in shCTL and shNa~V~1.5 cells (n = 10 separate experiments) and compared with a Mann--Whitney test. **B**, Mean ± s.e.m. peak INa recorded in 23 shCTL cells and in 20 shNa~V~1.5 cells under a depolarization from −100 to −5 mV (Mann--Whitney test). Representative currents are shown underneath. **C**, shCTL and shNa~V~1.5 cell growth and viability after 5 days, expressed relative to the shCTL cell line (n = 3 independent experiments). **D**, Cell viability of shCTL after 5 days of growth in presence of increasing concentrations of ranolazine, from 0.1 to 100 μM, and expressed relative to the control condition without ranolazine (vehicle). **E**, Effect of 30 μM tetrodotoxin (TTX) or 50 μM ranolazine (Rano) on shCTL and shNa~V~1.5 human breast cancer cell invasiveness (Kruskal-wallis analysis followed by a Dunn's test). **F**, shCTL and shNa~V~1.5 cells were cultured for 24 h on a Matrigel™-composed matrix treated with 50 μM ranolazine (Rano) or not. F-actin cytoskeleton was stained with phalloidin-AlexaFluor594. A cell circularity index was calculated using ImageJ© software (n = 138--238 cells analysed, Mann--Whitney test). **G**, shCTL cells were cultured on a Matrigel™-composed matrix containing DQ-Gelatin® for 24 h in presence or not of 50 μM ranolazine. A "Matrix-Focalized-degradation activity index" was calculated as being the number of pixels corresponding to the co-localization of F-actin condensation areas (F-actin cytoskeleton was stained with phalloidin-Alexa594) and focal spots of DQ-gelatin proteolysis (coloc) (7). Results are expressed relative to the control condition (CTL, N = 534 cells) without ranolazine (Rano, N = 375 cells) and compared using Mann--Whitney test. Representative pictures are shown on the left. Statistical significance is indicated as: \*p \<0.05; \*\*p \< 0.01 and \*\*\*p \< 0.001. NS stands for not statistically different.

Because Na~V~1.5 was proposed to promote metastases development from breast tumours, we assessed the importance of its expression in human breast cancer cells for the colonisation of organs. ShCTL or shNa~V~1.5 cells, both expressing the luciferase gene, were injected in the tail vein of NMRI nude mice. A third experimental group was set with mice injected with shCTL cells and receiving a daily intraperitoneal injection of ranolazine (50 mg/Kg -- 5 days per week). The colonisation of mice organs by human cancer cells was followed *in vivo*, every week for a total duration of 8 weeks, by bioluminescent imaging (BLI) after luciferin injection (Figure [3](#Fig3){ref-type="fig"}A). There was no statistical difference in the evolution of animal body weights between the three groups (Figure [3](#Fig3){ref-type="fig"}B). BLI performed in living animals indicated that shCTL cells, which express Na~V~1.5, strongly colonised and developed into the chest area (which was the case for 17 out of 18 mice). In contrast, shNa~V~1.5 cells led to a very weak signal (1/12 mice) or no signal at all (11/12 mice) in the chest area. Ranolazine, which inhibited Na~V~1.5 currents (Figure [1](#Fig1){ref-type="fig"}), significantly reduced total BLI signal in mice injected with shCTL cells. *In vitro*, ranolazine treatment did not interfere with luciferase activity in shCTL cells (Additional file [2](#MOESM2){ref-type="media"}: Figure S1) indicating that the BLI signal recorded was indeed strongly correlated with the abundance of cancer cells in mice organs. In this experimental group, BLI signal was recorded in 5 out of 8 mice (Figure [3](#Fig3){ref-type="fig"}C). At completion of the study, mice were sacrificed and isolated organs (lungs, brain, liver, bones from rachis/ribs and legs) were analysed *ex vivo*. In the shCTL group, all mice showed lung colonisation (18/18) and a small proportion also had bioluminescent signal in rachis and ribs (2/18) and in leg bones (2/18). In the shNa~V~1.5 group, 7 mice out of 12 had lung colonisation and one (1/12) had bioluminescent signal in rachis and ribs. In the ranolazine group, although 8/8 mice presented lung colonisation, bioluminescence was dramatically reduced by 77 ± 8%, at a level similar to the experimental suppression of Na~V~1.5 (inhibition of lung BLI by 97 ± 2%) (Figure [3](#Fig3){ref-type="fig"}D, [3](#Fig3){ref-type="fig"}E). In the ranolazine group, mice did not show BLI signal in other organs.Figure 3**Na** ~**V**~ **1.5 suppression, or ranolazine treatment, inhibit metastatic lung colonisation by breast cancer cells. A**, Representative bioluminescent imaging (BLI) measurement performed in the same NMRI nude mouse per condition from week 2 to week 8 after cancer cell injection. Mice were injected with shCTL MDA-MB-231-Luc cells (shCTL), or with shNa~V~1.5 MDA-MB-231-Luc cells (shNa~V~1.5) or with shCTL MDA-MB-231-Luc cells and treated (5 days/week) with ranolazine (50 mg/kg) (Rano) or vehicle (shCTL, shNa~V~1.5). **B**, Evolution of mice body weight during the experiments in the same conditions than in A. **C**, Mean *in vivo* BLI value (expressed in cpm) as a function of time recorded in the whole body of mice coming from the three groups indicated previously (shCTL, n = 18; shNa~V~1.5, n = 12; Rano, n = 8) (Statistical significance is indicated as: \*p \<0.05, Kruskal-Wallis analysis followed by Dunn's test). **D**, Representative BLI at completion of the study (8^th^ week after cells injection), in whole animals and *ex vivo* after lung isolation. **E**, BLI quantification of excised lungs. Box plots indicate the first quartile, the median, and the third quartile, squares indicate the mean (shCTL, n = 18; shNa~V~1.5, n = 12; Rano, n = 8) (Kruskal-Wallis analysis followed by Dunn's test).

While it is now well-established that Na~V~ channels are anomalously expressed in several epithelial tumours and are associated with metastasis occurrence and patient mortality \[[@CR12], [@CR16], [@CR17], [@CR23]\], the consequence of their expression on metastatic organ colonisation was not demonstrated so far. To our knowledge, this study is the first to clearly establish a link between Na~V~1.5 expression in human breast cancer cells and the colonisation of lungs *in vivo*. Furthermore, this study using ranolazine, a drug that is clinically used, shows that the pharmacological inhibition of Na~V~ channels could be effective in reducing metastastic colonisation with no apparent toxic effect. In conclusion, this study opens a new therapeutical concept for the management of cancer disease. Inhibitors of Na~V~ channels, already approved for other clinical use such as antiarrhythmics, anticonvulsants \[[@CR17]\] or anaesthetics \[[@CR24]\], or new molecules that are even more effective in blocking neonatal variants, could be of high interest in the prevention and/or reduction of metastatic spreading of cancer cells at the diagnosis of the primary tumour.
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Additional file 2: Figure S1: MDA-MB-231-shCTL cells expressing luciferase gene were seeded at different densities then treated for 24h with Ranolazine (50 μM, red circles) or not (black squares). (PDF 11 KB)
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